Evidence map›Paper›PMID 25320502›Full record

ReviewWorld journal of gastroenterology2014

Medical management of gastric cancer: a 2014 update.

Elena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Jeannelyn S Estrella, Mariela A Blum, Brian Badgwell, Prajnan Das, Shumei Song and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Gastrin and Gastric Cancer.Cellular and molecular gastroenterology and hepatology · 2017
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Elevated expression of immunity-related GTPase family M in gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Elena ElimovaElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Hironori ShiozakiElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Roopma WadhwaElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Kazuki SudoElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Qiongrong ChenElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Jeannelyn S EstrellaElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Mariela A BlumElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Brian BadgwellElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Prajnan DasElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Shumei SongElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
Jaffer A AjaniElena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States.
The University of Texas at Austin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy (United States), pre-and post-operative chemotherapy (Europe), and adjuvant chemotherapy after a D2 resection (Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population, the treatments remain limited. In the first line setting, the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy, with or without epirubicin or docetaxel. The results of targeted therapy trials have by and large been disappointing, but none of these trials looked at an appropriately enriched population. Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting, with either irinotecan, docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantHumansMolecular Targeted TherapyNeoadjuvant TherapyRisk FactorsStomach NeoplasmsSurvival AnalysisTreatment OutcomeChemoradiationChemotherapyGastric cancerLocalizedMetastatic

Identifiers

PMID25320502
PMCPMC4194548
OpenAlexW2133348184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.